Voyager Therapeutics has been granted a patent for a method involving adeno-associated virus capsid proteins with targeting peptide inserts for enhanced tropism to specific tissues. One claim includes an AAV capsid variant with increased tropism for brain cells compared to wild-type AAV9 capsid. GlobalData’s report on Voyager Therapeutics gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Data Insights Voyager Therapeutics Inc - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Voyager Therapeutics, Adeno-associated virus vectors was a key innovation area identified from patents. Voyager Therapeutics's grant share as of February 2024 was 15%. Grant share is based on the ratio of number of grants to total number of patents.

Enhanced aav capsid for brain cell targeting

Source: United States Patent and Trademark Office (USPTO). Credit: Voyager Therapeutics Inc

A recently granted patent (Publication Number: US11859200B2) discloses an adeno-associated virus (AAV) capsid variant designed to have increased tropism for brain cells or brain tissue compared to the wild-type AAV9 capsid. This variant, containing the specific amino acid sequence PLNGAVHLY in hypervariable loop VIII, aims to enhance the delivery of therapeutic agents to targeted areas within the brain. The patent further details the composition of AAV particles incorporating this capsid variant, along with a nucleotide sequence encoding various proteins, enzymes, or inhibitory RNA, all operably linked to specific promoters for targeted gene therapy applications.

Moreover, the patent outlines the potential applications of the AAV particle, emphasizing its ability to transduce specific regions of the brain with increased efficiency when administered intravenously. The disclosed AAV capsid variant demonstrates at least 5-fold enhanced tropism for brain cells or tissues compared to the wild-type AAV9 capsid, showcasing its potential for precise and effective gene delivery. Additionally, the patent includes claims related to the amino acid sequence identity of the capsid variant, highlighting its specificity and potential for customization based on therapeutic requirements. Overall, the patent provides a comprehensive framework for utilizing the AAV capsid variant in pharmaceutical compositions for targeted gene therapy, particularly in neurological disorders affecting regions such as the cerebral cortex, hippocampus, and brain stem.

To know more about GlobalData’s detailed insights on Voyager Therapeutics, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies